Metastasis to sigmoid colon mucosa and submucosa from serous borderline ovarian tumor: response to hormone therapy

被引:17
作者
Lee, EJ
Deavers, MT
Hughes, JI
Lee, JH
Kavanagh, JJ
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Gynecol Med Oncol, Houston, TX 77030 USA
[2] Sungkyunkwan Univ, Div Gynecol Oncol, Dept Obstet & Gynecol, Samsung Med Ctr, Seoul, South Korea
[3] Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
[4] Kelsey Seybold Clin, Dept Gastroenterol, Houston, TX USA
关键词
Arimidex; borderline; metastasis; ovarian cancer; sigmoid colon;
D O I
10.1111/j.1525-1438.2006.00206.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Distant metastasis to sites other than lymph nodes of borderline ovarian tumor is rare. We describe a case metastasized to sigmoid colon mucosa and submucosa. The metastatic lesion was detected incidentally by screening colonoscopy 7 years after the patient was treated for the primary tumor. The metastatic lesion responded well to treatment with oral Arimidex 1 mg/day. A follow-up colonoscopy with biopsy and imaging studies after 3 months of treatment revealed no evidence of disease in the sigmoid colon. This case showed that the sigmoid colon mucosa and submucosa should be considered as one of distant metastatic sites of a serous borderline ovarian tumor and the favorable response to Arimidex provides support the use of hormone therapy in women with serous borderline ovarian tumor.
引用
收藏
页码:295 / 299
页数:5
相关论文
共 51 条
[1]   Estrogen receptor expression is a common feature of ovarian borderline tumors [J].
AbuJawdeh, GM ;
Jacobs, TW ;
Niloff, J ;
Cannistra, SA .
GYNECOLOGIC ONCOLOGY, 1996, 60 (02) :301-307
[2]   HORMONAL PALLIATION OF CHEMORESISTANT OVARIAN-CANCER - 3 CONSECUTIVE PHASE-II TRIALS OF THE MID-ATLANTIC ONCOLOGY PROGRAM [J].
AHLGREN, JD ;
ELLISON, NM ;
GOTTLIEB, RJ ;
LALUNA, F ;
LOKICH, JJ ;
SINCLAIR, PR ;
UENO, W ;
WAMPLER, GL ;
YEUNG, KY ;
ALT, D ;
FRYER, JG .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (10) :1957-1968
[3]  
Balat, 1996, Cancer Control, V3, P137
[4]  
BARNHILL D, 1985, OBSTET GYNECOL, V65, P53
[5]  
BOSTWICK DG, 1986, CANCER, V58, P2052, DOI 10.1002/1097-0142(19861101)58:9<2052::AID-CNCR2820580916>3.0.CO
[6]  
2-5
[7]   Micropapillary serous ovarian carcinoma: Surgical management and clinical outcome [J].
Bristow, RE ;
Gossett, DR ;
Shook, DR ;
Zahurak, ML ;
Tomacruz, RS ;
Armstrong, DK ;
Montz, FJ .
GYNECOLOGIC ONCOLOGY, 2002, 86 (02) :163-170
[8]   Recurrent micropapillary serous ovarian carcinoma - The role of secondary cytoreductive surgery [J].
Bristow, RE ;
Gossett, DR ;
Shook, DR ;
Zahurak, ML ;
Tomacruz, RS ;
Armstrong, DK ;
Montz, FJ .
CANCER, 2002, 95 (04) :791-800
[9]   Metastatic serous borderline ovarian tumor in an internal mammary lymph node: A case report and review of the literature [J].
Chamberlin, MD ;
Eltabbakh, GH ;
Mount, SL ;
Leavitt, BJ .
GYNECOLOGIC ONCOLOGY, 2001, 82 (01) :212-215
[10]   BORDERLINE OVARIAN-TUMORS [J].
CHAMBERS, JT ;
MERINO, MJ ;
KOHORN, EI ;
SCHWARTZ, PE .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1988, 159 (05) :1088-1094